Mirum Pharmaceuticals, Inc. Common Stock (MIRM) Stock Price

MIRMStock

$98.08+35.23%52W

Market Cap$5.98B

P/E—

PEG Ratio—

Div yield—

Beta0.61

MIRM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-19.22%

Price vs S&P 500 (4W)-16.87%

VGM Score46.98

P/CF (Annual)115.18x

Book Value / Share (Quarterly)$3.98

P/TBV (Annual)75.93x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)89.13%

Cash Flow / Share (Quarterly)$-4.07

Price vs S&P 500 (YTD)10.49%

Gross Margin (TTM)81.72%

Net Profit Margin (TTM)-139.18%

EPS (TTM)$-14.55

10-Day Avg Trading Volume0.54M

EPS Excl Extra (TTM)$-14.55

EPS (Annual)$-0.47

ROI (Annual)-3.74%

Gross Margin (Annual)80.77%

Net Profit Margin (5Y Avg)-146.63%

Cash / Share (Quarterly)$6.77

Revenue Growth QoQ (YoY)37.92%

ROA (Last FY)-2.77%

Revenue Growth TTM (YoY)44.02%

EBITD / Share (TTM)$-14.21

ROE (5Y Avg)-55.51%

Operating Margin (TTM)-136.82%

Cash Flow / Share (Annual)$1.06

P/B Ratio26.52x

P/B Ratio (Quarterly)22.99x

Net Income / Employee (Annual)$-63,300

EV / Revenue (TTM)11.08x

Net Interest Coverage (TTM)-11.89x

ROA (TTM)-96.55%

EV / EBITDA (TTM)3249.18x

EPS Incl Extra (Annual)$-0.47

Current Ratio (Annual)2.67x

Quick Ratio (Quarterly)2.62x

3-Month Avg Trading Volume0.90M

52-Week Price Return35.23%

EV / Free Cash Flow (Annual)124.82x

Revenue / Employee (TTM)$1,675,000

Tangible BV / Share (Quarterly)$1.04

P/S Ratio (Annual)12.33x

Asset Turnover (Annual)0.62x

52-Week High$130.00

Operating Margin (5Y Avg)-125.44%

EPS Excl Extra (Annual)$-0.47

CapEx CAGR (5Y)32.91%

26-Week Price Return-7.97%

Quick Ratio (Annual)2.46x

13-Week Price Return-3.92%

Total Debt / Equity (Annual)0.98x

Current Ratio (Quarterly)2.86x

Enterprise Value$6.85B

Asset Turnover (TTM)0.69x

Book Value / Share Growth (5Y)0.98%

Revenue / Employee (Annual)$1,412,800

Inventory Turnover (Annual)4.24x

Pretax Margin (Annual)-4.11%

Cash / Share (Annual)$7.39

3-Month Return Std Dev49.72%

Gross Margin (5Y Avg)81.06%

Net Income / Employee (TTM)$-2,331,200

ROE (Last FY)-7.42%

Net Interest Coverage (Annual)-610.55x

EPS Basic Excl Extra (Annual)$-0.47

P/FCF (TTM)113.05x

Receivables Turnover (TTM)4.90x

EV / Free Cash Flow (TTM)119.33x

Total Debt / Equity (Quarterly)1.28x

EPS Incl Extra (TTM)$-14.55

Receivables Turnover (Annual)5.17x

ROI (TTM)-136.39%

P/S Ratio (TTM)10.40x

Pretax Margin (5Y Avg)-148.01%

Revenue / Share (Annual)$10.39

Tangible BV / Share (Annual)$1.04

Price vs S&P 500 (52W)16.92%

Year-to-Date Return22.45%

5-Day Price Return-4.11%

EPS Normalized (Annual)$-0.47

ROA (5Y Avg)-21.62%

Net Profit Margin (Annual)-4.48%

Month-to-Date Return-8.71%

Cash Flow / Share (TTM)$-4.10

EBITD / Share (Annual)$0.04

Operating Margin (Annual)-4.25%

LT Debt / Equity (Annual)0.98x

P/CF (TTM)117.05x

ROI (5Y Avg)-43.02%

LT Debt / Equity (Quarterly)1.28x

EPS Basic Excl Extra (TTM)$-14.55

P/TBV (Quarterly)75.93x

P/B Ratio (Annual)12.97x

Inventory Turnover (TTM)4.64x

Pretax Margin (TTM)-138.75%

Book Value / Share (Annual)$6.06

Price vs S&P 500 (13W)-6.72%

Beta0.61x

P/FCF (Annual)117.18x

Revenue / Share (TTM)$9.75

ROE (TTM)-289.33%

52-Week Low$63.23

vGradeF

gGradeB

mGradeC

vgmGradeC

MIRM Earnings Surprise History

Q2 25-0.12est. -0.33

Q3 250.05est. -0.16

Q4 25-0.12est. 0.06

Q1 26-1.08est. -0.35

Q2 26-0.80est. -0.75

MIRM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.29

4.32

4.35

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	$98.08
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Mirum Pharmaceuticals, Inc. Common Stock

Mirum Pharmaceuticals is a biopharmaceutical company developing therapies for rare and orphan liver diseases. The company markets Livmarli, an FDA-approved bile acid transporter inhibitor for cholestatic pruritus in Alagille syndrome patients. Mirum's pipeline includes maralixibat for pediatric cholestatic liver diseases and volixibat for adult patients with cholestatic conditions.